Patents by Inventor Takehiko Nakamura

Takehiko Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200206323
    Abstract: A therapeutic agent containing, as an effective component, a glycolytic enzyme which is different from a deficient protein of a patient with lysosomal storage disease as a subject and/or a glycolytic enzyme which does not have a mannose 6-phosphate moiety or a mannose moiety.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 2, 2020
    Applicants: THE NEMOURS FOUNDATION, SEIKAGAKU CORPORATION
    Inventors: Shunji TOMATSU, Kazuki SAWAMOTO, Takehiko NAKAMURA, Ikue KITAZAWA, Hideyuki FUTATSUMORI
  • Patent number: 9580384
    Abstract: The present invention provides a pest control agent, acaricide or fungicide that contains, as the active ingredient thereof, at least one type of compound selected from the aryloxyurea compounds represented by formula (V) (wherein R1 to R5 each independently represents an alkyl group or the like, X is a halogen atom or the like, n is an integer of 0 to 5, and Z is an oxygen atom or sulfur atom) or salts thereof.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 28, 2017
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Hironori Furukawa, Takehiko Nakamura, Tetsuo Tamai, Daisuke Hanai
  • Publication number: 20150203448
    Abstract: The present invention provides a pest control agent, acaricide or fungicide that contains, as the active ingredient thereof, at least one type of compound selected from the aryloxyurea compounds represented by formula (V) (wherein R1 to R5 each independently represents an alkyl group or the like, X is a halogen atom or the like, n is an integer of 0 to 5, and Z is an oxygen atom or sulfur atom) or salts thereof
    Type: Application
    Filed: April 2, 2015
    Publication date: July 23, 2015
    Applicant: Nippon Soda Co., Ltd.
    Inventors: Hironori Furukawa, Takehiko Nakamura, Tetsuo Tamai, Daisuke Hanai
  • Patent number: 9029601
    Abstract: The present invention provides a pest control agent, acaricide or fungicide that contains, as the active ingredient thereof, at least one type of compound selected from the aryloxyurea compounds represented by formula (V) (wherein R1 to R5 each independently represents an alkyl group or the like, X is a halogen atom or the like, n is an integer of 0 to 5, and Z is an oxygen atom or sulfur atom) or salts thereof.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: May 12, 2015
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Hironori Furukawa, Takehiko Nakamura, Tetsuo Tamai, Daisuke Hanai
  • Patent number: 9012493
    Abstract: The present invention provides a pest control agent having a novel skeleton, which can be synthesized industrially, and also has excellent biological activity and residual effects. Specifically, the present invention provides a 1-heterodiene derivative represented by Formula (1) or a salt thereof, and a pest control agent including, as an active ingredient, a 1-heterodiene derivative or a salt thereof.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: April 21, 2015
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Jyun Takahashi, Takehiko Nakamura, Masahiro Miyazawa, Isami Hamamoto, Jyun Kanazawa
  • Patent number: 8980912
    Abstract: The present invention provides a cyclic amine compound represented by formula (I) (in formula (I), Cy1 and Cy2 independently represent a C6-10 aryl group or a heterocyclyl group; R1a to R5a independently represent a hydrogen atom or an unsubstituted or substituted C1-6 alkyl group; R10, R11, R20 and R21 independently represent an unsubstituted or substituted C1-6 alkyl group, an unsubstituted or substituted C1-6 alkoxy group, a halogen atom or the like; m, n, p, and r each represent an integer of 0 to 5; and Y represents an oxygen atom or the like) or salt thereof, and an acaricide including the same.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: March 17, 2015
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Isami Hamamoto, Keiji Koizumi, Masahiro Kawaguchi, Hisashi Tanigawa, Takehiko Nakamura, Tomomi Kobayashi
  • Publication number: 20130231479
    Abstract: The present invention provides a pest control agent, acaricide or fungicide that contains, as the active ingredient thereof, at least one type of compound selected from the aryloxyurea compounds represented by formula (V) (wherein R1 to R5 each independently represents an alkyl group or the like, X is a halogen atom or the like, n is an integer of 0 to 5, and Z is an oxygen atom or sulfur atom) or salts thereof.
    Type: Application
    Filed: October 6, 2011
    Publication date: September 5, 2013
    Inventors: Hironori Furukawa, Takehiko Nakamura, Tetsuo Tamai, Daisuke Hanai
  • Publication number: 20120309964
    Abstract: The present invention provides a cyclic amine compound represented by formula (I) (in formula (I), Cy1 and Cy2 independently represent a C6-10 aryl group or a heterocyclyl group; R1a to R5a independently represent a hydrogen atom or an unsubstituted or substituted C1-6 alkyl group; R10, R11, R20 and R21 independently represent an unsubstituted or substituted C1-6 alkyl group, an unsubstituted or substituted C1-6 alkoxy group, a halogen atom or the like; m, n, p, and r each represent an integer of 0 to 5; and Y represents an oxygen atom or the like) or salt thereof, and an acaricide including the same.
    Type: Application
    Filed: February 24, 2011
    Publication date: December 6, 2012
    Inventors: Isami Hamamoto, Keiji Koizumi, Masahiro Kawaguchi, Hisashi Tanigawa, Takehiko Nakamura, Tomomi Kobayashi
  • Publication number: 20120225895
    Abstract: The present invention provides a pest control agent having a novel skeleton, which can be synthesized industrially, and also has excellent biological activity and residual effects. Specifically, the present invention provides a 1-heterodiene derivative represented by Formula (1) or a salt thereof, and a pest control agent including, as an active ingredient, a 1-heterodiene derivative or a salt thereof.
    Type: Application
    Filed: November 9, 2010
    Publication date: September 6, 2012
    Inventors: Jyun Takahashi, Takehiko Nakamura, Masahiro Miyazawa, Isami Hamamoto, Jyun Kanazawa
  • Publication number: 20110306709
    Abstract: The present invention provides a primer composition for sealant in which the coating quality can be visually inspected and which can sufficiently fade on exposure to the light. The primer composition for sealant use comprises (A) a binder resin and (B) one type or two or more types of pigment selected from the group composed of curcumin pigment, monascus pigment, chlorophyll, paprika pigment, marigold pigment and caramel pigment.
    Type: Application
    Filed: February 22, 2010
    Publication date: December 15, 2011
    Inventors: Tomoyuki Torii, Kiyoshi Nakayama, Yoshimitsu Nakayama, Takehiko Nakamura, Masaaki Murase
  • Patent number: 7695940
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: April 13, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20090069553
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: March 12, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20090061511
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: March 5, 2009
    Applicant: BIOGEN IDEC INC.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20090018314
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 15, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Patent number: 7438906
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: October 21, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20080193447
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 14, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Patent number: 7332163
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: February 19, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Patent number: 7223392
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: May 29, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20070065435
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 7, 2006
    Publication date: March 22, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • Publication number: 20070065434
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 7, 2006
    Publication date: March 22, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura